ANSELL GRIMM & AARON, PC’s dedicated Controlled Substances & Regulatory Law Practice Group has an in-depth understanding of the laws related to the production, sale, use, regulation and legalization of controlled substances, including:  hemp, cannabis, and psychedelics. Controlled substances law remains a multifaceted and complex field with, at times, conflicting regulations from different governing bodies.  Our attorneys are prepared to assist in all aspects of this emerging field and are committed to helping our clients understand their rights and the opportunities in this complex and evolving area of law.

The lawyers of ANSELL GRIMM & AARON, PC’s Controlled Substances & Regulatory Law Practice Group handle matters including, but not limited to:

• Licensing
• Corporate Formation and Governance
• Commercial Leasing
• Federal Enforcement Actions
• Contract Negotiation and Drafting
• Financing
• Litigation and Dispute Resolution
• Regulatory and Municipal Compliance

We have an established record in the the controlled substances space enabling us to serve our clients unlike any other local law firm.  By example, ANSELL GRIMM & AARON, PC co-hosted the first-ever Cannabis Symposium in New Jersey which drew nearly a thousand people (two other Symposia followed).  Joshua S. Bauchner, head of the practice group, is co-chair of the New Jersey State Bar Association Cannabis Law Committee, has spoken at the Cannabis World Congress and Business Expo at the Jacob Javits Center, and has presented CLE’s on cannabis at the NY and NJ State Bar Associations, among other fora across the country.  He also was honored with the New Jersey Law Journal’s Innovator of the Year Award for his work in the cannabis space.

The Firm filed a pro-bono amicus brief in the United States Supreme Court in the matter of Washington v. Barr, on behalf of several non-profit organizations representing former national and international professional athletes in support of a constitutional challenge to the federal government’s continued refusal to remove marijuana from Schedule I of the Controlled Substances Act, even though millions of Americans use marijuana on a regular basis to manage debilitating health conditions in accordance with State, territorial, and local laws. Unfortunately, with the passing of Justice Ginsberg, petitioners were unable to secure the four votes necessary to secure review.

In recent years, efforts to decriminalize and legalize the use of psilocybin (colloquially known as “hallucinogenic mushrooms”) for medical, recreational and scientific purposes has been advancing rapidly. In the State of New Jersey, the potential passage of the “Psilocybin Behavioral Health Access and Services Act” (the “Psilocybin Behavioral Act”), introduced by Senate President, Nick Scutari in June of 2022 would see such legalization and sale of hallucinogenic mushrooms in New Jersey businesses and medical facilities, similar to the State’s recent success in recreational cannabis facilities.  If passed, the Psilocybin Behavioral Act would authorize the production of psilocybin for therapeutic use under a controlled environment, and decriminalize and expunge past convictions for certain psilocybin related conduct, including possession.

Although the Psilocybin Behavioral Act posits itself as mental health, rather than revenue generation for the State, it does take some inspiration from the current Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization (“CREAMM”) Act. Specifically, applicants will be eligible to pursue four different types of licenses, including, a psilocybin product manufacturer, psilocybin service center operator, psilocybin testing laboratory, and psilocybin service facilitator, as well as a psilocybin worker permit.

The firm also has been covered by numerous media outlets and published regularly on the topic.

Publications:

• SCOTUS Confronted With Racist and Discriminatory History of Cannabis Criminalization
• Easy Route Available for Resolving Medical Marijuana Facility Delays
• Attorneys Joshua S. Bauchner and Rahool Patel discuss workplace drug testing in IndustryWeek.
• Staying Ahead of New Cannabis Laws
• Cannabis Law Practice Chief Joshua S. Bauchner discusses cannabis and the law on Law & Crime Network
  
• Managing Medical Marijuana in the Workplace
• Despite possible legalization in N.J., medical marijuana should be expanded, protected
• Where the Gibson Taxpayers Went Wrong – Law360
• With the Election of Gov. Murphy, NJ is on the Path to Legalization – Freedom Leaf Magazine
• Client Alert: New Jersey accepting applications for up to six new, vertically integrated, medical marijuana facilities.
• Client Alert: New Jersey Introduces two new cannabis bills
• How NY And NJ Medical Cannabis Regulations Are Evolving – Law360
• New York’s Proposed Expansion Of Medical Marijuana Regulations – MJNews
• Trump and Sessions Need to Take a Deep Breath (and Perhaps Inhale) When It Comes to Pot Regulations – High Times
• New Jersey’s Cannabis Industry is Growing: Where does it Grow from Here?  – High Times
• Colorado Indicates Cannabis is no Substitute for Alcohol – High Times
• Cannabis Regulation in Nevada: A Guide for Potential Entrants into the Marketplace – High Times